Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 385

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 385
---
123 |     |         89 |
|                                                 |     |      2,055 |     |      2,523 |     |      1,666 |

Employee numbers

The average number of
staff employed by the Group during the financial year amounted to:

| Schedule for average number of employed staff |     |      |     |      |     |      |
|                                               |     | 2023 |     | 2022 |     | 2021 |
| Research and development                      |     |   16 |     |   22 |     |   15 |
| General and administration                    |     |    5 |     |    5 |     |    5 |
|                                               |     |   21 |     |   27 |     |   20 |

Key management
personnel compensation

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Group, including the Directors of the Company, including the Chief Executive Officer and Chief Scientific Officer.

| Schedule of Management Personnel Compensation |     |            |     |            |     |            |
|                                               |     | 2023 £’000 |     | 2022 £’000 |     | 2021 £’000 |
| Short term employee benefits                  |     |        677 |     |        668 |     |        658 |
| Post-employment benefits                      |     |         21 |     |         21 |     |         27 |
| Share-based payment                           |     |         22 |     |         53 |     |         61 |
|                                               |     |        720 |     |        742 |     |        746 |

During the year no
Directors (2022: 0; 2012: 1) participated in a defined contribution pension scheme. Pension contributions in the above note include
those of the Chief Scientific Officer.

Emoluments disclosed above include the following
amounts in respect of the highest paid Director.

| Schedule of emoluments       
 disclosed                    |     |            |     |            |     |            |
|                              |     | 2023 £’000 |     | 2022 £’000 |     | 2021 £’000 |
| Short term employee benefits |     |        252 |     |        238 |     |        223 |
| Post-employment benefits     |     |          – |     |          – |